|Articles|June 15, 2015
- BioPharm International-06-15-2015
- Volume 2015 eBook
- Issue 1
Biopharma Advances Demand Specialized Expertise
Contract service providers share insights on biopharma market developments and the implications of biosimilar drug approvals.
Advertisement
The approval of the first biosimilar in the United States, as well as continuing consolidation in the biopharma and contract development and manufacturing markets, are just two indicators of the ongoing evolution of biopharmaceutical development. Representatives of contract service providers shared observations, trends and projections with BioPharm International.
Download
.
Articles in this issue
over 10 years ago
QRM Tools for Contract Biomanufacturingover 10 years ago
Fill/Finish Trendsover 10 years ago
Protecting Intellectual Property in Engagements with CMOsover 10 years ago
Taking a “Development-by-Design” Approach to Cell TherapiesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
4
